The FDA has approved a groundbreaking gene therapy treatment for a rare form of inherited blindness, marking a historic milestone in genetic medicine.
The treatment targets patients with mutations in the RPE65 gene, which causes progressive vision loss starting in childhood. The one-time treatment has shown remarkable results in restoring functional vision.
Clinical Results
In clinical trials, 93% of patients showed significant improvement in their ability to navigate low-light environments, with many experiencing improvements that allowed them to perform daily activities independently for the first time.
"This approval represents a watershed moment in medicine," said FDA Commissioner. "We are now able to directly correct the genetic cause of a disease."